Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study

Christophe Bureau, Danielle Adebayo, Mael Chalret de Rieu, Laure Elkrief, Dominique Valla, Markus Peck-Radosavljevic, Anne McCune, Victor Vargas, Macarena Simon-Talero, Juan Cordoba, Paolo Angeli, Silvia Rosi, Stewart MacDonald, Massimo Malago, Maria Stepanova, Zobair M. Younossi, Claudia Trepte, Randall Watson, Oleg Borisenko, Sun SunNeil Inhaber, Rajiv Jalan

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

© 2017 European Association for the Study of the Liver Background and Aims: Patients with refractory ascites (RA) require repeated large volume paracenteses (LVP), which involves frequent hospital visits and is associated with a poor quality-of-life. This study assessed safety and efficacy of an automated, low-flow pump (alfapump® [AP]) compared with LVP standard of care [SoC]. Methods: A randomized controlled trial, in seven centers, with six month patient observation was conducted. Primary outcome was time to first LVP. Secondary outcomes included paracentesis requirement, safety, health-related quality-of-life (HRQoL), and survival. Nutrition, hemodynamics, and renal injury biomarkers were assessed in a sub-study at three months. Results: Sixty patients were randomized and 58 were analyzed (27 AP, 31 SoC, mean age 61.9 years, mean MELD 11.7). Eighteen patients were included in the sub-study. Compared with SoC, median time to first LVP was not reached after six months in the AP group, meaning a significant reduction in LVP requirement for the AP patients (AP, median not reached; SoC, 15.0 days (HR 0.13; 95% CI 13.0–22.0; p <0.001), and AP patients also showed significantly improved Chronic Liver Disease Questionnaire (CLDQ) scores compared with SoC patients (p <0.05 between treatment arms). Improvements in nutritional parameters were observed for hand-grip strength (p = 0.044) and body mass index (p <0.001) in the sub-study. Compared with SoC, more AP patients reported adverse events (AEs; 96.3% vs. 77.4%, p = 0.057) and serious AEs (85.2 vs. 45.2%, p = 0.002). AEs consisted predominantly of acute kidney injury in the immediate post-operative period, and re-intervention for pump related issues, and were treatable in most cases. Survival was similar in AP and SoC. Conclusions: The AP system is effective for reducing the need for paracentesis and improving quality of life in cirrhotic patients with RA. Although the frequency of SAEs (and by inference hospitalizations) was significantly higher in the AP group, they were generally limited and did not impact survival. Lay summary: The alfapump® moves abdominal fluid into the bladder from where it is then removed by urination. Compared with standard treatment, the alfapump reduces the need for large volume paracentesis (manual fluid removal by needle) in patients with medically untreatable ascites. This can improve life quality for these patients. www.clinicaltrials.gov#NCT01528410.
Original languageEnglish
Pages (from-to)940-949
JournalJournal of Hepatology
Volume67
Issue number5
DOIs
Publication statusPublished - 1 Nov 2017

Keywords

  • Liver cirrhosis
  • Paracentesis
  • Refractory ascites

Fingerprint Dive into the research topics of 'Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study'. Together they form a unique fingerprint.

Cite this